FREDERICK, MD--(Marketwired - Mar 13, 2017) - BioElectronics Corporation (OTC PINK: BIEL), the maker of advanced
noninvasive bioelectronic pain management medical devices, is pleased to announce that its devices are being featured at the
Australian Pharmacy Professional Conference and Trade Exhibition. The conference and trade exhibition is the largest
pharmaceutical event in Australia with 232 exhibitors including Proctor & Gamble, Johnson & Johnson, Bayer, Mundipharma, Pfizer,
Sanofi, Kimberly Clark, Scholl Orthaheel, and Perrigo.
Our recent US FDA over-the-counter market clearance has attracted new interest and strong product support from existing
international distributors to reach the 1.5 billion worldwide chronic pain sufferers. Our noninvasive bioelectronic product
line includes ActiPatch® Musculoskeletal Pain Therapy and Smart Insole™ Heel Pain Therapy. The flagship product of BioElectronics
Corporation is the ActiPatch® Musculoskeletal Pain Therapy, the ideal nonprescription drug-free medical device for chronic pain
at $29.95 for 720-hours (90 8-hour treatments) of superior 24-hour pain relief.
Rob Gourley of EvoMed (www.evomed.com.au) said, "We are excited to be
part of such an important trade exhibition to showcase BioElectronics' products to our retail and hospital accounts."
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of ActiPatch® Therapy, for back pain and other
musculoskeletal complaints, RecoveryRx® Devices for chronic wounds and post-operative wound care, and Allay® Menstrual Pain
Therapy. For clinical and more information, please visit www.bielcorp.com. Amazon website and the Company's website www.tryActiPatch.com have available the Company's Award Winning Try & Tell 7-Day Trial
ActiPatch Musculoskeletal Pain Relief for $9.95. The 7-Day Trial Device introduces consumers to significant long-lasting pain
relief that allows a full night's sleep and restoration of daily activities without any harmful side effects.